Amyris (NASDAQ:AMRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, March 13th.
According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “
Other equities analysts have also recently issued research reports about the company. HC Wainwright set a $15.00 price target on Amyris and gave the stock a “buy” rating in a research note on Wednesday, November 29th. ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Cowen reiterated a “hold” rating and set a $4.00 price target on shares of Amyris in a report on Wednesday, November 29th. Finally, B. Riley initiated coverage on Amyris in a report on Thursday, January 25th. They issued a “buy” rating and a $8.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $8.19.
Shares of Amyris stock opened at $6.74 on Tuesday. The company has a debt-to-equity ratio of -0.78, a current ratio of 0.92 and a quick ratio of 0.82. Amyris has a one year low of $1.86 and a one year high of $10.65.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.24). The firm had revenue of $80.59 million during the quarter, compared to the consensus estimate of $68.14 million. The business’s revenue for the quarter was up 262.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.09) earnings per share. analysts predict that Amyris will post -1.01 EPS for the current year.
In related news, insider John Melo sold 10,776 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total value of $50,431.68. Following the sale, the insider now owns 83,172 shares of the company’s stock, valued at approximately $389,244.96. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 11.30% of the company’s stock.
A number of institutional investors have recently bought and sold shares of AMRS. Carl Domino Inc acquired a new position in shares of Amyris during the third quarter valued at $182,000. Creative Planning bought a new stake in Amyris in the fourth quarter valued at about $188,000. KBC Group NV increased its holdings in Amyris by 228.4% in the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares during the last quarter. Compagnie Lombard Odier SCmA increased its holdings in shares of Amyris by 60.0% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 39,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Amyris in the fourth quarter worth about $451,000. 22.27% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Amyris (NASDAQ:AMRS) Stock Rating Upgraded by Zacks Investment Research” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2018/03/22/amyris-amrs-rating-increased-to-hold-at-zacks-investment-research.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.